US 12,600,770 B2 · Antibodies to connective tissue growth factor (CTGF) and uses thereof

Abstract

The present disclosure generally relates to anti-CTGF (connective tissue growth factor) antibodies or antigen-binding fragments thereof. Exemplary anti-CTGF antibodies disclosed herein address the need for treatments of conditions modulated by CTGF signaling. In some aspects, the anti-CTGF antibodies or antigen-binding fragments thereof are for diagnostic and/or therapeutic use, for example in a subject in need thereof, such as a human.

An anti-CTGF antibody or an antigen-binding fragment thereof, comprising:

i. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
220, an L-CDR2 having the amino acid sequence of SEQ ID NO:
221, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
222;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
105, an H-CDR2 having the amino acid sequence of SEQ ID NO:
106, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
107;
or
ii. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
100, an L-CDR2 having the amino acid sequence of SEQ ID NO:
101, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
102;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
105, an H-CDR2 having the amino acid sequence of SEQ ID NO:
106, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
107;
or
iii. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
110, an L-CDR2 having the amino acid sequence of SEQ ID NO:
111, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
112;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
105, an H-CDR2 having the amino acid sequence of SEQ ID NO:
106, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
107;
or
iv. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
100, an L-CDR2 having the amino acid sequence of SEQ ID NO:
101, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
102;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
115, an H-CDR2 having the amino acid sequence of SEQ ID NO:
116, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
117;
or
v. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
110, an L-CDR2 having the amino acid sequence of SEQ ID NO:
111, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
112;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
115, an H-CDR2 having the amino acid sequence of SEQ ID NO:
116, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
117;
or
vi. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
220, an L-CDR2 having the amino acid sequence of SEQ ID NO:
221, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
222;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
115, an H-CDR2 having the amino acid sequence of SEQ ID NO:
116, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
117;
or
vii. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
100, an L-CDR2 having the amino acid sequence of SEQ ID NO:
101, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
102;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
145, an H-CDR2 having the amino acid sequence of SEQ ID NO:
146, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
147;
or
viii. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
110, an L-CDR2 having the amino acid sequence of SEQ ID NO:
111, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
112;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
145, an H-CDR2 having the amino acid sequence of SEQ ID NO:
146, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
147;
or
ix. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO:
220, an L-CDR2 having the amino acid sequence of SEQ ID NO:
221, and an L-CDR3 having the amino acid sequence of SEQ ID NO:
222;
and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO:
145, an H-CDR2 having the amino acid sequence of SEQ ID NO:
146, and an H-CDR3 having the amino acid sequence of SEQ ID NO:
147.

77 more elements

Antibodies to connective tissue growth factor (CTGF) and uses thereof

Life of this patent

Antibodies to connective tissue growth factor (CTGF) and uses thereof

Life of this patent

Abstract

Claims29